2014-03-21 21:22:47 UTC

Gastroenterology Podcast March 2014: Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Chronic Hepatitis C

A phase-3 study in the March issue of Gastroenterology examined the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Dr. Kuemmerle discusses the results with first author Dr. Maria Buti; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Buti M, Agarwal K, Horsmans Y, et al. Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. Gastroenterology 2014; March; 146(3): 744-753
Abstract

 

 

Duration: 14.52m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on Hepatitis C

Payer and Provider Workshops in HCV and HIV (Seattle, WA)

Nov. 14, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Indianapolis, IN)

Nov. 8, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Tampa, FL)

Oct. 24, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.